NASH | Boehringer Ingelheim TW
NASH
Non-alcoholic steatohepatitis (NASH) is caused by a metabolic-induced inflammation of the liver and is one of the major causes of liver fibrosis and cirrhosis. Its symptoms are often silent or non-specific to NASH, making it difficult to diagnose. It is an area of high unmet medical need with no approved treatments currently available. NASH is the more serious form of non-alcoholic fatty liver disease (NAFLD), which is the most common liver disease in Western industrialized nations, affecting one out of four adults. NASH and NAFLD are especially prevalent in, but not limited to, people with metabolic disorders such as type 2 diabetes and obesity. The prevalence of NASH has been estimated to range up to 444 million people worldwide.
Links
[Read more](/content/tw/disclaimer/market?path=https%3A%2F%2Fwww.boehringer-ingelheim.com%2Fhuman-pharma%2Fscience-focus%2Fcardiometabolic-research "Cardiometabolic Research"/index.html)
Cardiometabolic Research
[See more](/content/tw/disclaimer/market?path=https%3A%2F%2Fwww.boehringer-ingelheim.com%2Fhuman-pharma%2Fdisease-focus%2Fcardiometabolic-research-focus "Cardiometabolic Research Focus"/index.html)
Cardiometabolic Research Focus
Downloads
[Read more
Opens in new tab](/content/sites/default/files/tw/2023-04/CardioMetabolic_infographic_Update_2021.pdf "Read more: Our Patient-Centric Approach to CardioMetabolic Disease Research"/index.html)